Determining the role of sarcomeric proteins in facioscapulohumeral muscular dystrophy: A study protocol

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Lassche, Saskia ^a   Ottenheijm, Coen A C ^b   Voermans, Nicol C ^a   Westeneng, Henk Jan ^c   Janssen, Barbara H ^a   van der Maarel, Silvère M ^d   Hopman, Maria T ^a   Padberg, George W ^a   Stienen, Ger J M ^b   van Engelen, Baziel G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Facioscapulohumeral muscular dystrophy; Myofilament; Oculopharyngeal muscular dystrophy; Sarcomere; Skeletal muscle; Sporadic inclusion body myositis

Indexed keywords

ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CONTROL; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; HUMAN; HUMAN TISSUE; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSICAL ACTIVITY; PILOT STUDY; PROTEIN ANALYSIS; SARCOMERE; TIBIALIS ANTERIOR MUSCLE;

ADULT; CALCIUM; CASE-CONTROL STUDIES; FEMALE; HUMANS; ISOMETRIC CONTRACTION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE FATIGUE; MUSCLE FIBERS, SKELETAL; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOSIN HEAVY CHAINS; QUESTIONNAIRES; SKIN; YOUNG ADULT;

EID: 84885336685     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-144     Document Type: Article

References (47)

1. Emery AE. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991, 1(1):19-29. 10.1016/0960-8966(91)90039-U, 1822774.
2. van der Maarel SM, Frants RR, Padberg GW. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta 2007, 1772(2):186-194. 10.1016/j.bbadis.2006.05.009, 16837171.
3. Padberg GW. Facioscapulohumeral dystrophy 1982, Leiden, the, Netherlands: Leiden University.
4. Pandya S, King WM, Tawil R. Facioscapulohumeral dystrophy. Phys Ther 2008, 88(1):105-113. 10.2522/ptj.20070104, 17986494.
5. Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camano P, Dauwerse JG, Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010, 329(5999):1650-1653. 10.1126/science.1189044, 20724583.
6. van der Maarel SM, Tawil R, Tapscott SJ. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med 2011, 17(5):252-258. 10.1016/j.molmed.2011.01.001, 3092836, 21288772.
7. Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M, Harper PS, Upadhyaya M. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet 1995, 4(5):951-958. 10.1093/hmg/4.5.951, 7633457.
8. de Greef JC, Lemmers RJ, Camano P, Day JW, Sacconi S, Dunand M, van Engelen BG, Kiuru-Enari S, Padberg GW, Rosa AL, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010, 75(17):1548-1554. 10.1212/WNL.0b013e3181f96175, 2974464, 20975055.
9. Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, Amell AM, van der Vliet PJ, Almomani R, Straasheijm KR, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nature genetics 2012, 44(12):1370-1374. 10.1038/ng.2454, 3671095, 23143600.
10. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004, 113(1):115-123. 300763, 14702115.
11. Wallace LM, Garwick SE, Mei W, Belayew A, Coppee F, Ladner KJ, Guttridge D, Yang J, Harper SQ. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Annals Neurology 2011, 69(3):540-552.
12. Geng LN, Yao Z, Snider L, Fong AP, Cech JN, Young JM, van der Maarel SM, Ruzzo WL, Gentleman RC, Tawil R, et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell 2012, 22(1):38-51. 10.1016/j.devcel.2011.11.013, 3264808, 22209328.
13. Vanderplanck C, Ansseau E, Charron S, Stricwant N, Tassin A, Laoudj-Chenivesse D, Wilton SD, Coppee F, Belayew A. The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 2011, 6(10):e26820. 10.1371/journal.pone.0026820, 3203905, 22053214.
14. Lokireddy S, McFarlane C, Ge X, Zhang H, Sze SK, Sharma M, Kambadur R. Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. Mol Endocrinol 2011, 25(11):1936-1949. 10.1210/me.2011-1124, 21964591.
15. Liu Q, Jones TI, Tang VW, Brieher WM, Jones PL. Facioscapulohumeral muscular dystrophy region gene-1 (FRG-1) is an actin-bundling protein associated with muscle-attachment sites. J Cell Sci 2010, 123(Pt 7):1116-1123. 2844320, 20215405.
16. Hanel ML, Sun CY, Jones TI, Long SW, Zanotti S, Milner D, Jones PL. Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic nuclear and sarcomeric protein. Differ res Biol Diversity 2011, 81(2):107-118.
17. Gabellini D, D'Antona G, Moggio M, Prelle A, Zecca C, Adami R, Angeletti B, Ciscato P, Pellegrino MA, Bottinelli R, et al. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 2006, 439(7079):973-977.
18. Wuebbles RD, Hanel ML, Jones PL. FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy. Disease Models Mechanisms 2009, 2(5-6):267-274. 2675802, 19383939.
19. Lassche S, Stienen GJ, Irving TC, van der Maarel SM, Voermans NC, Padberg GW, Granzier H, van Engelen BG, Ottenheijm CA. Sarcomeric dysfunction contributes to muscle weakness in facioscapulohumeral muscular dystrophy. Neurology 2013, 80(8):733-737. 10.1212/WNL.0b013e318282513b, 23365058.
20. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscular Disord: NMD 2010, 20(2):142-147. 10.1016/j.nmd.2009.11.003, 20074951.
21. Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001, 56(3):336-340. 10.1212/WNL.56.3.336, 11171898.
22. Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, Piazzo N, Servidei S, Vigneti E, Pasceri V, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Annals Neurology 1999, 45(6):751-757.
23. van Overveld PG, Enthoven L, Ricci E, Rossi M, Felicetti L, Jeanpierre M, Winokur ST, Frants RR, Padberg GW, van der Maarel SM. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Annals Neurology 2005, 58(4):569-576.
24. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res 2007, 62(5):571-579. 10.1016/j.jpsychores.2006.11.014, 17467412.
25. van der Werf SP, Prins JB, Vercoulen JH, van der Meer JW, Bleijenberg G. Identifying physical activity patterns in chronic fatigue syndrome using actigraphic assessment. J Psychosom Res 2000, 49(5):373-379. 10.1016/S0022-3999(00)00197-5, 11164063.
26. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and rheumatism 1980, 23(2):137-145. 10.1002/art.1780230202, 7362664.
27. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003, 35(8):1381-1395. 10.1249/01.MSS.0000078924.61453.FB, 12900694.
28. Jacobs HM, Luttik A, Touw Otten FW, De Melker RA. The sickness impact profile; results of an evaluation study of the Dutch version]. Nederlands tijdschrift voor geneeskunde 1990, 134(40):1950-1954.
29. Vanderiet K, Adriaensen H, Carton H, Vertommen H. The McGill Pain Questionnaire constructed for the Dutch language (MPQ-DV). Preliminary data concerning reliability and validity. Pain 1987, 30(3):395-408. 10.1016/0304-3959(87)90027-3, 3670884.
30. Council MR. Aids to the examination of the peripheral nervous system, Memorandum no 45. edn 1981, London, UK: Her Majesty's Stationery Office.
31. Berard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases, construction and validation study. Neuromuscul Disord 2005, 15(7):463-470. 10.1016/j.nmd.2005.03.004, 16106528.
32. Enright PL. The six-minute walk test. Respir Care 2003, 48(8):783-785.
33. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991, 39(2):142-148.
34. Degens H, Sanchez Horneros JM, Heijdra YF, Dekhuijzen PN, Hopman MT. Skeletal muscle contractility is preserved in COPD patients with normal fat-free mass. Acta physiologica Scandinavica 2005, 184(3):235-242. 10.1111/j.1365-201X.2005.01447.x, 15954991.
35. Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010, 20(10):2447-2460. 10.1007/s00330-010-1799-2, 2940021, 20422195.
36. Kan HE, Scheenen TW, Wohlgemuth M, Klomp DW, van Loosbroek-Wagenmans I, Padberg GW, Heerschap A. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2009, 19(5):357-362. 10.1016/j.nmd.2009.02.009, 19329315.
37. The FSH-DY Group A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997, 48(1):38-46. The FSH-DY Group.
38. Ottenheijm CA, Hooijman P, DeChene ET, Stienen GJ, Beggs AH, Granzier H. Altered myofilament function depresses force generation in patients with nebulin-based nemaline myopathy (NEM2). J Struct Biol 2010, 170(2):334-343. 10.1016/j.jsb.2009.11.013, 2856782, 19944167.
39. Stienen GJ, Kiers JL, Bottinelli R, Reggiani C. Myofibrillar ATPase activity in skinned human skeletal muscle fibres: fibre type and temperature dependence. J Physiol 1996, 493(Pt 2):299-307. 1158918, 8782097.
40. Ottenheijm CA, Lawlor MW, Stienen GJ, Granzier H, Beggs AH. Changes in cross-bridge cycling underlie muscle weakness in patients with tropomyosin 3-based myopathy. Hum Mol Genet 2011, 20(10):2015-2025. 10.1093/hmg/ddr084, 3080611, 21357678.
41. Chandra M, Mamidi R, Ford S, Hidalgo C, Witt C, Ottenheijm C, Labeit S, Granzier H. Nebulin alters cross-bridge cycling kinetics and increases thin filament activation: a novel mechanism for increasing tension and reducing tension cost. J Biol Chem 2009, 284(45):30889-30896. 10.1074/jbc.M109.049718, 2781488, 19736309.
42. Ottenheijm CA, Witt CC, Stienen GJ, Labeit S, Beggs AH, Granzier H. Thin filament length dysregulation contributes to muscle weakness in nemaline myopathy patients with nebulin deficiency. Hum Mol Genet 2009, 18(13):2359-2369. 10.1093/hmg/ddp168, 2694687, 19346529.
43. Ottenheijm CA, Knottnerus AM, Buck D, Luo X, Greer K, Hoying A, Labeit S, Granzier H. Tuning passive mechanics through differential splicing of titin during skeletal muscle development. Biophys J 2009, 97(8):2277-2286. 10.1016/j.bpj.2009.07.041, 2764098, 19843460.
44. Warren CM, Krzesinski PR, Greaser ML. Vertical agarose gel electrophoresis and electroblotting of high-molecular-weight proteins. Electrophoresis 2003, 24(11):1695-1702. 10.1002/elps.200305392, 12783444.
45. Ottenheijm CA, Heunks LM, Geraedts MC, Dekhuijzen PN. Hypoxia-induced skeletal muscle fiber dysfunction: role for reactive nitrogen species. Am J Physiol Lung Cell Mol Physiol 2006, 290(1):L127-L135.
46. Ottenheijm CA, Heunks LM, Sieck GC, Zhan WZ, Jansen SM, Degens H, de Boo T, Dekhuijzen PN. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172(2):200-205. 10.1164/rccm.200502-262OC, 2718467, 15849324.
47. Lahmers S, Wu Y, Call DR, Labeit S, Granzier H. Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res 2004, 94(4):505-513. 10.1161/01.RES.0000115522.52554.86, 14707027.